DOCSLIB.ORG

Reportable Diseases List for Clinical Providers to Report by Phone: 401-222-2577 | After Hours: 401-272-5952 | Cases May Also Be Reported Electronically Or by Mail

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reportable Diseases List for Clinical Providers to Report by Phone: 401-222-2577 | After Hours: 401-272-5952 | Cases May Also Be Reported Electronically Or by Mail Division of Preparedness, Response, Infectious Disease, and Emergency Medical Services 3 Capitol Hill, Room 106, Providence, RI 02908 Reportable Diseases List for Clinical Providers To report by phone: 401-222-2577 | After Hours: 401-272-5952 | Cases may also be reported electronically or by mail. To report by secure fax: STDs: 401-222-1105 | Animal Bites: 401-222-2477 | All Other Diseases: 401-222-2488 Rhode Island State Health Laboratories support is available by calling 401-222-5600. For more information and to download forms, visit http://health.ri.gov/diseases/infectious/resultsreportable.php Report the following diseases and conditions IMMEDIATELY by phone upon recognition or strong suspicion of disease. Laboratory confirmation is not necessary prior to report being filed. Diseases in blue are potential agents of bioterrorism. • Animal bites • Hantavirus Pulmonary • Ricin poisoning • Anthrax Syndrome • Scombroid poisoning • Arboviral infections (e.g., West • Hepatitis A2 • Smallpox (Variola) Nile, Eastern Equine • Measles (Rubeola) • Staphylococcus aureus inva- Encephalitis, Powassan, Zika, • Melioidosis sive infections: VRSA/VISA Chikungunya, Yellow Fever) • Meningococcal disease- • Staphylococcal enterotoxin • Botulism invasive1 B poisoning • Brucellosis • Middle East Respiratory • Tularemia • Cholera Syndrome (MERS) • Typhoid fever (Salmonella • Ciguatera • Outbreaks and clusters typhi) • Clostridium perfringens epsilon • Paralytic shellfish poisoning • Unexplained deaths toxin • Plague (possibly due to unidentified • Diphtheria • Poliomyelitis infectious causes) • Encephalitis (infectious causes) • Q-Fever • Vibriosis • Glanders • Rabies • Viral hemorrhagic fevers (e.g., Ebola, Lassa, Marburg) ______________________________________________________________________________________________________________ Report the following diseases and conditions within 4 days of recognition of disease3: • Acute flaccid myelitis • Hepatitis B, C, D, E (all acute • Pneumococcal disease1 • Anaplasmosis cases, and pregnant women • Rickettsiosis, including Rocky • Babesiosis (all species) with chronic illness), and Mountain Spotted Fever • Campylobacteriosis unspecified viral hepatitis2 • Rubella (including congenital • Carbapenem resistant • HIV 1 and 2. Report pregnancy rubella) organisms (CRE) in women with HIV. Report by • Salmonellosis • Chancroid confidential mail only. • Shigellosis • Chlamydia trachomatis • Influenza associated deaths, • Streptococcal disease • Coccidioidomycosis hospitalizations, and novel (invasive Group A & B)1 • Cryptosporidiosis virus infections • Streptococcal Toxic Shock • Cyclosporiasis • Latent Tuberculosis Infection Syndrome • Dengue virus • Legionellosis • Syphilis-all stages including • Ehrlichiosis • Leptospirosis neurosyphilis and congenital 1 • Escherichia coli, Shiga toxin- • Listeriosis syphilis producing (STEC) • Lyme disease • Tetanus • Giardiasis • Lymphogranuloma Venereum • Toxic Shock Syndrome • Gonorrhea • Malaria • Transmissible spongiform • Granuloma Inguinale • Meningitis (aseptic, bacterial, encephalopathies (including (Klebsiella granulomatis) viral, or fungal) Creutzfeldt Jakob disease) • Haemophilus influenzae • Mumps • Trichinosis disease, all serotypes1 • Ornithosis/Psittacosis • Tuberculosis disease • Hansen's disease or Leprosy • Pelvic inflammatory disease • Varicella • Hemolytic uremic syndrome • Pertussis • Yersiniosis _________________________________________________________________________________________________________________________________________________________________________ 1 Invasive disease only: confirmed by isolation from blood, CSF, pericardial fluid, pleural fluid, peritoneal fluid, joint fluid, or other normally sterile site. 2 Also report AST, ALT, and bilirubin 3 Report patient’s name, address, gender, race, ethnicity, date of birth, age, and phone number with attending physician’s name and phone number April 2018 .
Load more

Recommended publications
  • Parinaud's Oculoglandular Syndrome
    Tropical Medicine and Infectious Disease Case Report Parinaud’s Oculoglandular Syndrome: A Case in an Adult with Flea-Borne Typhus and a Review M. Kevin Dixon 1, Christopher L. Dayton 2 and Gregory M. Anstead 3,4,* 1 Baylor Scott & White Clinic, 800 Scott & White Drive, College Station, TX 77845, USA; [email protected] 2 Division of Critical Care, Department of Medicine, University of Texas Health, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA; [email protected] 3 Medical Service, South Texas Veterans Health Care System, San Antonio, TX 78229, USA 4 Division of Infectious Diseases, Department of Medicine, University of Texas Health, San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA * Correspondence: [email protected]; Tel.: +1-210-567-4666; Fax: +1-210-567-4670 Received: 7 June 2020; Accepted: 24 July 2020; Published: 29 July 2020 Abstract: Parinaud’s oculoglandular syndrome (POGS) is defined as unilateral granulomatous conjunctivitis and facial lymphadenopathy. The aims of the current study are to describe a case of POGS with uveitis due to flea-borne typhus (FBT) and to present a diagnostic and therapeutic approach to POGS. The patient, a 38-year old man, presented with persistent unilateral eye pain, fever, rash, preauricular and submandibular lymphadenopathy, and laboratory findings of FBT: hyponatremia, elevated transaminase and lactate dehydrogenase levels, thrombocytopenia, and hypoalbuminemia. His condition rapidly improved after starting doxycycline. Soon after hospitalization, he was diagnosed with uveitis, which responded to topical prednisolone. To derive a diagnostic and empiric therapeutic approach to POGS, we reviewed the cases of POGS from its various causes since 1976 to discern epidemiologic clues and determine successful diagnostic techniques and therapies; we found multiple cases due to cat scratch disease (CSD; due to Bartonella henselae) (twelve), tularemia (ten), sporotrichosis (three), Rickettsia conorii (three), R.
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Reportable Disease Surveillance in Virginia, 2013
    Reportable Disease Surveillance in Virginia, 2013 Marissa J. Levine, MD, MPH State Health Commissioner Report Production Team: Division of Surveillance and Investigation, Division of Disease Prevention, Division of Environmental Epidemiology, and Division of Immunization Virginia Department of Health Post Office Box 2448 Richmond, Virginia 23218 www.vdh.virginia.gov ACKNOWLEDGEMENT In addition to the employees of the work units listed below, the Office of Epidemiology would like to acknowledge the contributions of all those engaged in disease surveillance and control activities across the state throughout the year. We appreciate the commitment to public health of all epidemiology staff in local and district health departments and the Regional and Central Offices, as well as the conscientious work of nurses, environmental health specialists, infection preventionists, physicians, laboratory staff, and administrators. These persons report or manage disease surveillance data on an ongoing basis and diligently strive to control morbidity in Virginia. This report would not be possible without the efforts of all those who collect and follow up on morbidity reports. Divisions in the Virginia Department of Health Office of Epidemiology Disease Prevention Telephone: 804-864-7964 Environmental Epidemiology Telephone: 804-864-8182 Immunization Telephone: 804-864-8055 Surveillance and Investigation Telephone: 804-864-8141 TABLE OF CONTENTS INTRODUCTION Introduction ......................................................................................................................................1
    [Show full text]
  • HIV (Human Immunodeficiency Virus)
    TABLE OF CONTENTS AFRICAN TICK BITE FEVER .........................................................................................3 AMEBIASIS .....................................................................................................................4 ANTHRAX .......................................................................................................................5 ASEPTIC MENINGITIS ...................................................................................................6 BACTERIAL MENINGITIS, OTHER ................................................................................7 BOTULISM, FOODBORNE .............................................................................................8 BOTULISM, INFANT .......................................................................................................9 BOTULISM, WOUND .................................................................................................... 10 BOTULISM, OTHER ...................................................................................................... 11 BRUCELLOSIS ............................................................................................................. 12 CAMPYLOBACTERIOSIS ............................................................................................. 13 CHANCROID ................................................................................................................. 14 CHLAMYDIA TRACHOMATIS INFECTION .................................................................
    [Show full text]
  • Know Your Abcs: a Quick Guide to Reportable Infectious Diseases in Ohio
    Know Your ABCs: A Quick Guide to Reportable Infectious Diseases in Ohio From the Ohio Administrative Code Chapter 3701-3; Effective August 1, 2019 Class A: Diseases of major public health concern because of the severity of disease or potential for epidemic spread – report immediately via telephone upon recognition that a case, a suspected case, or a positive laboratory result exists. • Anthrax • Measles • Rubella (not congenital) • Viral hemorrhagic fever • Botulism, foodborne • Meningococcal disease • Severe acute respiratory (VHF), including Ebola virus • Cholera • Middle East Respiratory syndrome (SARS) disease, Lassa fever, Marburg • Diphtheria Syndrome (MERS) • Smallpox hemorrhagic fever, and • Influenza A – novel virus • Plague • Tularemia Crimean-Congo hemorrhagic infection • Rabies, human fever Any unexpected pattern of cases, suspected cases, deaths or increased incidence of any other disease of major public health concern, because of the severity of disease or potential for epidemic spread, which may indicate a newly recognized infectious agent, outbreak, epidemic, related public health hazard or act of bioterrorism. Class B: Disease of public health concern needing timely response because of potential for epidemic spread – report by the end of the next business day after the existence of a case, a suspected case, or a positive laboratory result is known. • Amebiasis • Carbapenemase-producing • Hepatitis B (perinatal) • Salmonellosis • Arboviral neuroinvasive and carbapenem-resistant • Hepatitis C (non-perinatal) • Shigellosis
    [Show full text]
  • Melioidosis in Northern Tanzania: an Important Cause of Febrile Illness?
    Melioidosis and serological evidence of exposure to Burkholderia pseudomallei among patients with fever, northern Tanzania Michael Maze Department of Medicine University of Otago, Christchurch Melioidosis Melioidosis caused by Burkholderia pseudomallei • Challenging to identify when cultured Soil reservoir, with human infection from contact with contaminated water Most infected people are asymptomatic: 1 clinical illness for 4,500 antibody producing exposures Febrile illness with a variety of presentations and bacteraemia is present in 40-60% of people with acute illness Estimated 89,000 deaths globally Gavin Koh CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=4975784 Laboratory diagnosis of febrile inpatients, northern Tanzania, 2007-8 (n=870) Malaria (1.6%) Bacteremia (9.8%) Mycobacteremia (1.6%) Fungemia (2.9%) Brucellosis (3.5%) Leptospirosis (8.8%) Q fever (5.0%) No diagnosis (50.1%) Spotted fever group rickettsiosis (8.0%) Typhus group rickettsiosis (0.4%) Chikungunya (7.9%) Crump PLoS Neglect Trop Dis 2013; 7: e2324 Predicted environmental suitability for B. pseudomallei in East Africa Large areas of Africa are predicted to be highly suitable for Burkholderia pseudomallei East Africa is less suitable but pockets of higher suitability including northern Tanzania Northern Tanzania Increasing suitability for B. pseudomallei Limmathurotsakul Nat Microbiol. 2016;1(1). Melioidosis epidemiology in Africa Paucity of empiric data • Scattered case reports • Report from Kilifi, Kenya identified 4 bacteraemic cases from 66,000 patients who had blood cultured1 • 5.9% seroprevalence among healthy adults in Uganda2 • No reports from Tanzania 1. Limmathurotsakul Nat Microbiol. 2016;1(1). 2. Frazer J R Army Med Corps. 1982;128(3):123-30.
    [Show full text]
  • Communicable Disease Case Counts 2014-2018
    Report 4: Table of Diseases Comparing A Given Timeframe for Past 5 Years Case Types: Individual Cases Only Case Status: Confirmed, Probable Year: 2014-2018 Investigation Status: Completed Display Interval: By Year Jurisdictions: Mid-Michigan District Report Type: Counts Disease Group Disease 2014 2015 2016 2017 2018 Total AIDS/HIV AIDS, Aggregate 0 0 0 0 0 0 HIV/AIDS, Adult 3 2 0 0 0 5 HIV/AIDS, Pediatric 0 0 0 0 0 0 Subtotal 3 2 0 0 0 5 Foodborne Amebiasis 1 0 0 1 0 2 Botulism - Foodborne 0 0 0 0 0 0 Campylobacter 14 31 17 20 12 94 Cryptosporidiosis 7 6 13 15 7 48 Escherichia coli 0157:H7 (Pre-2011)* 0 0 0 0 0 0 Giardiasis 19 10 8 14 3 54 Listeriosis 0 0 0 0 0 0 Listeriosis (2014- 2017)* 1 0 0 0 0 1 Listeriosis (Pre-2014)* 0 0 0 0 0 0 Norovirus 4 1 13 7 5 30 Paratyphoid Fever 0 0 0 0 0 0 Salmonellosis 10 12 24 20 20 86 Shiga toxin, E. Coli, Non O157 (Pre- 2011)* 0 0 0 0 0 0 Shiga toxin, E. Coli, Unsp (Pre-2011)* 0 0 0 0 0 0 Shiga toxin-producing Escherichia coli -- (STEC) 4 1 4 0 3 12 Shigellosis 3 5 13 5 2 28 Typhoid Fever 0 0 0 0 0 0 Yersinia enteritis 0 1 1 0 0 2 Subtotal 63 67 93 82 52 357 Influenza Flu Like Disease* 0 0 0 0 0 0 Influenza 37 63 49 231 278 658 Influenza, 2009 Novel* 0 0 0 0 0 0 Influenza, Novel 0 0 0 0 0 0 Subtotal 37 63 49 231 278 658 Meningitis Meningitis - Aseptic 6 21 11 9 13 60 Meningitis - Bacterial Other 1 3 2 3 7 16 Meningococcal Disease 0 1 0 0 0 1 Streptococcus pneumoniae, Inv 8 20 25 20 24 97 Subtotal 15 45 38 32 44 174 01-17-2019 1 of 5 Disease Group Disease 2014 2015 2016 2017 2018 Total Other Acute Flaccid
    [Show full text]
  • Tick-Borne Disease Working Group 2020 Report to Congress
    2nd Report Supported by the U.S. Department of Health and Human Services • Office of the Assistant Secretary for Health Tick-Borne Disease Working Group 2020 Report to Congress Information and opinions in this report do not necessarily reflect the opinions of each member of the Working Group, the U.S. Department of Health and Human Services, or any other component of the Federal government. Table of Contents Executive Summary . .1 Chapter 4: Clinical Manifestations, Appendices . 114 Diagnosis, and Diagnostics . 28 Chapter 1: Background . 4 Appendix A. Tick-Borne Disease Congressional Action ................. 8 Chapter 5: Causes, Pathogenesis, Working Group .....................114 and Pathophysiology . 44 The Tick-Borne Disease Working Group . 8 Appendix B. Tick-Borne Disease Working Chapter 6: Treatment . 51 Group Subcommittees ...............117 Second Report: Focus and Structure . 8 Chapter 7: Clinician and Public Appendix C. Acronyms and Abbreviations 126 Chapter 2: Methods of the Education, Patient Access Working Group . .10 to Care . 59 Appendix D. 21st Century Cures Act ...128 Topic Development Briefs ............ 10 Chapter 8: Epidemiology and Appendix E. Working Group Charter. .131 Surveillance . 84 Subcommittees ..................... 10 Chapter 9: Federal Inventory . 93 Appendix F. Federal Inventory Survey . 136 Federal Inventory ....................11 Chapter 10: Public Input . 98 Appendix G. References .............149 Minority Responses ................. 13 Chapter 11: Looking Forward . .103 Chapter 3: Tick Biology, Conclusion . 112 Ecology, and Control . .14 Contributions U.S. Department of Health and Human Services James J. Berger, MS, MT(ASCP), SBB B. Kaye Hayes, MPA Working Group Members David Hughes Walker, MD (Co-Chair) Adalbeto Pérez de León, DVM, MS, PhD Leigh Ann Soltysiak, MS (Co-Chair) Kevin R.
    [Show full text]
  • IAP Guidelines on Rickettsial Diseases in Children
    G U I D E L I N E S IAP Guidelines on Rickettsial Diseases in Children NARENDRA RATHI, *ATUL KULKARNI AND #VIJAY Y EWALE; FOR INDIAN A CADEMY OF PEDIATRICS GUIDELINES ON RICKETTSIAL DISEASES IN CHILDREN COMMITTEE From Smile Healthcare, Rehabilitation and Research Foundation, Smile Institute of Child Health, Ramdaspeth, Akola; *Department of Pediatrics, Ashwini Medical College, Solapur; and #Dr Yewale Multispeciality Hospital for Children, Navi Mumbai; for Indian Academy of Pediatrics “Guidelines on Rickettsial Diseases in Children” Committee. Correspondence to: Dr Narendra Rathi, Consultant Pediatrician, Smile Healthcare, Rehabilitation & Research Foundation, Smile Institute of Child Health, Ramdaspeth, Akola, Maharashtra, India. [email protected]. Objective: To formulate practice guidelines on rickettsial diseases in children for pediatricians across India. Justification: Rickettsial diseases are increasingly being reported from various parts of India. Due to low index of suspicion, nonspecific clinical features in early course of disease, and absence of easily available, sensitive and specific diagnostic tests, these infections are difficult to diagnose. With timely diagnosis, therapy is easy, affordable and often successful. On the other hand, in endemic areas, where healthcare workers have high index of suspicion for these infections, there is rampant and irrational use of doxycycline as a therapeutic trial in patients of undifferentiated fevers. Thus, there is a need to formulate practice guidelines regarding rickettsial diseases in children in Indian context. Process: A committee was formed for preparing guidelines on rickettsial diseases in children in June 2016. A meeting of consultative committee was held in IAP office, Mumbai and scientific content was discussed. Methodology and results were scrutinized by all members and consensus was reached.
    [Show full text]
  • NYC Health Code and Rules – Article 11- Reportable Diseases And
    ARTICLE 11 REPORTABLE DISEASES AND CONDITIONS §11.01 Definitions. §11.03 Diseases and conditions of public health interest that are reportable. §11.04 Report of First-Episode Psychosis §11.05 Reports. §11.07 Immunization Registry. §11.09 Blood Lead Reporting and Children's Blood Lead Registry. §11.10 Neonatal herpes simplex. §11.11 Confidentiality of reports and records. §11.13 Duty of physician to advise case, suspect case, carrier, suspect carrier and contact. §11.15 Control measures; duty to exclude; exclusion orders. §11.17 Control measures; duty to isolate; and isolation, quarantine and examination orders. §11.19 Typhoid and paratyphoid fever; exclusion. §11.21 Tuberculosis; reporting, examination, treatment, exclusion, removal and detention. §11.23 Removal and detention of cases, contacts and carriers who are or may be a danger to public health; other orders. §11.25 Reports and control of animal diseases communicable to humans. §11.27 Control of animals affected with rabies. §11.29 Rabies: compulsory vaccination. §11.31 Acts likely to spread disease prohibited. §11.33 Congenital Syphilis. §11.01 Definitions. When used in this article: (a) "Carrier" means an individual who, without showing any evidence of clinical disease, harbors and is capable of transmitting an infectious agent and may be a potential source of infection to others. (b) "Case" means, depending on the context, (1) an individual who, based on clinical, laboratory and/or epidemiologic evidence or other recognized public health criteria, has a disease or condition of public health interest that is reportable to the Department pursuant to this article or any other applicable law or regulation, or (2) an instance of such a reportable disease or condition occurring in an individual.
    [Show full text]
  • Laboratory Diagnostics of Rickettsia Infections in Denmark 2008–2015
    biology Article Laboratory Diagnostics of Rickettsia Infections in Denmark 2008–2015 Susanne Schjørring 1,2, Martin Tugwell Jepsen 1,3, Camilla Adler Sørensen 3,4, Palle Valentiner-Branth 5, Bjørn Kantsø 4, Randi Føns Petersen 1,4 , Ole Skovgaard 6,* and Karen A. Krogfelt 1,3,4,6,* 1 Department of Bacteria, Parasites and Fungi, Statens Serum Institut (SSI), 2300 Copenhagen, Denmark; [email protected] (S.S.); [email protected] (M.T.J.); [email protected] (R.F.P.) 2 European Program for Public Health Microbiology Training (EUPHEM), European Centre for Disease Prevention and Control (ECDC), 27180 Solnar, Sweden 3 Scandtick Innovation, Project Group, InterReg, 551 11 Jönköping, Sweden; [email protected] 4 Virus and Microbiological Special Diagnostics, Statens Serum Institut (SSI), 2300 Copenhagen, Denmark; [email protected] 5 Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut (SSI), 2300 Copenhagen, Denmark; [email protected] 6 Department of Science and Environment, Roskilde University, 4000 Roskilde, Denmark * Correspondence: [email protected] (O.S.); [email protected] (K.A.K.) Received: 19 May 2020; Accepted: 15 June 2020; Published: 19 June 2020 Abstract: Rickettsiosis is a vector-borne disease caused by bacterial species in the genus Rickettsia. Ticks in Scandinavia are reported to be infected with Rickettsia, yet only a few Scandinavian human cases are described, and rickettsiosis is poorly understood. The aim of this study was to determine the prevalence of rickettsiosis in Denmark based on laboratory findings. We found that in the Danish individuals who tested positive for Rickettsia by serology, the majority (86%; 484/561) of the infections belonged to the spotted fever group.
    [Show full text]
  • Tularemia – Epidemiology
    This first edition of theWHO guidelines on tularaemia is the WHO GUIDELINES ON TULARAEMIA result of an international collaboration, initiated at a WHO meeting WHO GUIDELINES ON in Bath, UK in 2003. The target audience includes clinicians, laboratory personnel, public health workers, veterinarians, and any other person with an interest in zoonoses. Tularaemia Tularaemia is a bacterial zoonotic disease of the northern hemisphere. The bacterium (Francisella tularensis) is highly virulent for humans and a range of animals such as rodents, hares and rabbits. Humans can infect themselves by direct contact with infected animals, by arthropod bites, by ingestion of contaminated water or food, or by inhalation of infective aerosols. There is no human-to-human transmission. In addition to its natural occurrence, F. tularensis evokes great concern as a potential bioterrorism agent. F. tularensis subspecies tularensis is one of the most infectious pathogens known in human medicine. In order to avoid laboratory-associated infection, safety measures are needed and consequently, clinical laboratories do not generally accept specimens for culture. However, since clinical management of cases depends on early recognition, there is an urgent need for diagnostic services. The book provides background information on the disease, describes the current best practices for its diagnosis and treatment in humans, suggests measures to be taken in case of epidemics and provides guidance on how to handle F. tularensis in the laboratory. ISBN 978 92 4 154737 6 WHO EPIDEMIC AND PANDEMIC ALERT AND RESPONSE WHO Guidelines on Tularaemia EPIDEMIC AND PANDEMIC ALERT AND RESPONSE WHO Library Cataloguing-in-Publication Data WHO Guidelines on Tularaemia.
    [Show full text]